VSE Capital Markets

Dr Reddys Laboratories Ltd

NSE : DRREDDYBSE : 500124ISIN CODE : INE089A01023Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln

BSE4,901.50 -180.60 (-3.55%)

PREV CLOSE (₹) 5,082.10

OPEN PRICE (₹) 5,100.00

BUY PRICE4,900.00(×3)

SELL PRICE 4,901.70(×6)

VOLUME 19,403

TODAY'S RANGE (₹)5,100.004,835.65

52 WK RANGE(₹)5,514.652,497.60

NSE4,895.00 -187.40 (-3.69%)

PREV CLOSE( ₹ ) 5,082.40

OPEN PRICE (₹) 5,052.40

BUY PRICE 4,895.00(×3)

SELL PRICE4,896.25(×12)

VOLUME 841,304

TODAY'S RANGE(₹) 5,052.404,832.80

52 WK RANGE (₹)5,512.652,495.05

Stock Summary

MARKET CAP (₹ CR)	84,514.47
P/E	34.42
BOOK VALUE (₹)	979.38
DIV (%)	500.00
MARKET LOT	1.00

EPS (TTM)	147.67
PRICE/BOOK	5.19
DIV YIELD.(%)	0.49
FACE VALUE (₹)	5.00
DELIVERABLES (%)	13.11

Background Information

Incorporation Year	1984
Registered Office	8-2-337 Road No 3,Banjara Hills Hyderabad,Telangana-500034
Telephone	91-40-49002900,Managing Director
Fax	91-40-49002999
Chairman	K Satish Reddy
Managing Director	G V Prasad
Company Secretary	Sandeep Poddar
Auditor	S R Batliboi & Associates LLP
Face Value	5
Market Lot	1
Listing	BSE,MSEI ,New York,NSE,
Registrar	Big Share Services Pvt Ltd 3rd Flr 306 Rightwin,Amrutha Ville,Somajiguda,Hyderabad-500082

MF Holdings

Scheme Name	Hold(%)
SBI ETF Nifty 50	1.05
AXIS Long Term Equity Fund	3.10
Aditya Birla SL Equity Fund	6.02
Mirae Asset Large Cap Fund	2.74
SBI Equity Hybrid Fund	1.46

News & Announcements

Date	News
16-Jan-2021	Dr Reddys Lab gets DCGI nod for Phase 3 COVID vaccine trial
16-Jan-2021	Dr. Reddys receives DCGI approval to conduct Phase 3 clinical trial for Sputnik V vaccine in India
12-Jan-2021	Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Press Release
11-Jan-2021	Dr Reddys Laboratories Ltd - Dr. Reddys Laboratories Limited - Press Release

Share Holding

Peer Group

Sun Pharmaceuticals Industries Ltd 570.10 ( -2.80)	M.Cap (₹ in Cr) 140732.99
Cipla Ltd 843.40 ( 0.75)	M.Cap (₹ in Cr) 67508.80
Aurobindo Pharma Ltd 962.95 ( -3.51)	M.Cap (₹ in Cr) 58476.67
Cadila Healthcare Ltd 462.75 ( -0.88)	M.Cap (₹ in Cr) 47793.42
Biocon Ltd 378.25 ( -1.16)	M.Cap (₹ in Cr) 45924.00

3rd Floor,Fortune Tower,Sayajigunj, Vadodara 390020, Gujarat, India

Telephone: +91 265 2361534

Customer Care Number: +91 265 2361474

Customer Care Timings: Monday to Friday 8:30am to 6:15pm

Email Address: vse@vselindia.com / compliance@vselindia.com

Attention Investors:

"Prevent Unauthorized transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day .......... Issued in the interest of investors
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
KYC is one time exercise while dealing in securities market - once KYC is done through a SEBI registered intermediary (broker , DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.
Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

For any complaints pertaining to securities broking please write to compliance@vselindia.com, for DP related to dp@vselindia.com. Please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI.

Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed.